Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2024

Collaborative Arrangements and Licensing Agreements [Abstract]

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with AstraZeneca	$	129,759		$	202,236		$	79,160
Percentage of total revenue		18	%		26	%		13	%

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with Biogen	$	368,058		$	350,146		$	366,696
Percentage of total revenue		52	%		44	%		62	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with GSK	$	—		$	15,000		$	—
Percentage of total revenue		0	%		2	%		0	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Novartis (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with Novartis	$	37,762		$	30,194		$	237
Percentage of total revenue		5	%		4	%	Less than 1%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with Roche	$	39,871		$	48,838		$	67,202
Percentage of total revenue		6	%		6	%		11	%

Otsuka [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the year ended December 31, 2024, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amount):

	Year Ended December 31,
	2024			2023
Revenue from our relationship with Otsuka	$	46,856		$	56,480
Percentage of total revenue		7	%		7	%

Alnylam [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Alnylam (in thousands, except percentage amounts):

	Year Ended December 31,
	2024			2023			2022
Revenue from our relationship with Alnylam	$	8,110		$	28,426		$	21,389
Percentage of total revenue		1	%		4	%		4	%